Marco A Ell, Miriam A Schiele, Nicola Iovino, Katharina Domschke
{"title":"Epigenetics of Fear, Anxiety and Stress - Focus on Histone Modifications.","authors":"Marco A Ell, Miriam A Schiele, Nicola Iovino, Katharina Domschke","doi":"10.2174/1570159X21666230322154158","DOIUrl":null,"url":null,"abstract":"<p><p>Fear-, anxiety- and stress-related disorders are among the most frequent mental disorders. Given substantial rates of insufficient treatment response and often a chronic course, a better understanding of the pathomechanisms of fear-, anxiety- and stress-related disorders is urgently warranted. Epigenetic mechanisms such as histone modifications - positioned at the interface between the biological and the environmental level in the complex pathogenesis of mental disorders - might be highly informative in this context. The current state of knowledge on histone modifications, chromatin-related pharmacology and animal models modified for genes involved in the histone-related epigenetic machinery will be reviewed with respect to fear-, anxiety- and stress-related states. Relevant studies, published until 30th June 2022, were identified using a multi-step systematic literature search of the Pub- Med and Web of Science databases. Animal studies point towards histone modifications (e.g., H3K4me3, H3K9me1/2/3, H3K27me2/3, H3K9ac, H3K14ac and H4K5ac) to be dynamically and mostly brain region-, task- and time-dependently altered on a genome-wide level or gene-specifically (<i>e.g., Bdnf</i>) in models of fear conditioning, retrieval and extinction, acute and (sub-)chronic stress. Singular and underpowered studies on histone modifications in human fear-, anxiety- or stress-related phenotypes are currently restricted to the phenotype of PTSD. Provided consistent validation in human phenotypes, epigenetic biomarkers might ultimately inform indicated preventive interventions as well as personalized treatment approaches, and could inspire future innovative pharmacological treatment options targeting the epigenetic machinery improving treatment response in fear-, anxiety- and stressrelated disorders.</p>","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":"843-865"},"PeriodicalIF":4.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845084/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1570159X21666230322154158","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Fear-, anxiety- and stress-related disorders are among the most frequent mental disorders. Given substantial rates of insufficient treatment response and often a chronic course, a better understanding of the pathomechanisms of fear-, anxiety- and stress-related disorders is urgently warranted. Epigenetic mechanisms such as histone modifications - positioned at the interface between the biological and the environmental level in the complex pathogenesis of mental disorders - might be highly informative in this context. The current state of knowledge on histone modifications, chromatin-related pharmacology and animal models modified for genes involved in the histone-related epigenetic machinery will be reviewed with respect to fear-, anxiety- and stress-related states. Relevant studies, published until 30th June 2022, were identified using a multi-step systematic literature search of the Pub- Med and Web of Science databases. Animal studies point towards histone modifications (e.g., H3K4me3, H3K9me1/2/3, H3K27me2/3, H3K9ac, H3K14ac and H4K5ac) to be dynamically and mostly brain region-, task- and time-dependently altered on a genome-wide level or gene-specifically (e.g., Bdnf) in models of fear conditioning, retrieval and extinction, acute and (sub-)chronic stress. Singular and underpowered studies on histone modifications in human fear-, anxiety- or stress-related phenotypes are currently restricted to the phenotype of PTSD. Provided consistent validation in human phenotypes, epigenetic biomarkers might ultimately inform indicated preventive interventions as well as personalized treatment approaches, and could inspire future innovative pharmacological treatment options targeting the epigenetic machinery improving treatment response in fear-, anxiety- and stressrelated disorders.
恐惧、焦虑和压力相关障碍是最常见的精神障碍之一。鉴于恐惧、焦虑和压力相关障碍的治疗反应不足率很高,而且往往是慢性病程,因此迫切需要更好地了解恐惧、焦虑和压力相关障碍的病理机制。在精神障碍复杂的发病机制中,组蛋白修饰等表观遗传机制处于生物和环境水平的交界处,在这方面可能极具参考价值。我们将针对与恐惧、焦虑和压力相关的状态,回顾组蛋白修饰、染色质相关药理学和动物模型中涉及组蛋白相关表观遗传机制的基因修饰方面的知识现状。通过对 Pub- Med 和 Web of Science 数据库进行多步骤系统文献检索,确定了截至 2022 年 6 月 30 日发表的相关研究。动物研究表明,在恐惧条件反射、复元和消退、急性和(亚)慢性应激模型中,组蛋白修饰(如H3K4me3、H3K9me1/2/3、H3K27me2/3、H3K9ac、H3K14ac和H4K5ac)在全基因组水平或特定基因(如Bdnf)上发生动态改变,且大多与脑区、任务和时间有关。关于组蛋白修饰在人类恐惧、焦虑或应激相关表型中的作用的研究目前仅限于创伤后应激障碍的表型。如果在人类表型中得到一致的验证,表观遗传生物标志物最终可能会为预防性干预措施和个性化治疗方法提供依据,并为未来针对表观遗传机制的创新药物治疗方案提供灵感,从而改善恐惧、焦虑和应激相关疾病的治疗反应。
期刊介绍:
Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience.
The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.